Quarter Comparison
Revenue
Operating Income
Gross Margin
Net Margin
Income Statement
Balance Sheet
Earnings Release
EX-99.1 2 amrx-q22026ex991.htm EX-99.1 Document Exhibit 99.1 AMNEAL REPORTS SECOND QUARTER 2026 FINANCIAL RESULTS – Q2 2026 Net Revenue of $796 million; GAAP Net Income of $58 million; Diluted Income per Share of $0.18 – – Adjusted EBITDA of $206 million; Adjusted Diluted EPS of $0.30 – – Raising 20
EX-99.1 2 amrx-q22026ex991.htm EX-99.1 Document Exhibit 99.1 AMNEAL REPORTS SECOND QUARTER 2026 FINANCIAL RESULTS – Q2 2026 Net Revenue of $796 million; GAAP Net Income of $58 million; Diluted Income per Share of $0.18 – – Adjusted EBITDA of $206 million; Adjusted Diluted EPS of $0.30 – – Raising 2026 Full Year Guidance – – Successful Debt Repricing in July Reduces Interest Cost – BRIDGEWATER, NJ, July 30, 2026 - Amneal Pharmaceuticals, Inc. (Nasdaq: AMRX) (“Amneal” or the “Company”) today announced its results for the second quarter ended June 30, 2026. “Amneal delivered strong, broad-based performance in the second quarter and first half of 2026, reflecting the strength of our diversified portfolio and the contributions from multiple growth drivers. This robust first-half performance gives us confidence to raise our full-year 2026 guidance for the second time this year. We are excited...
Source
Exhibit EX-99.1
0001723128-26-000025
Filed July 30, 2026 at 10:15 AM UTC. The figures above are from the audited statements, not from this release.